Janssen Pharmaceuticals, a part of Johnson & Johnson, has acquired rights to investigational eye-disorder gene therapy called HMR59 from Hemera Biosciences for an undisclosed sum.
Biogen has entered into a $1.525bn worth deal with Sage Therapeutics for the development and commercialisation of breakthrough therapies in depression and movement disorders.
Telix Pharmaceuticals announces it has entered into an agreement with Scintec Diagnostics to acquire TheraPharm GmbH (‘TheraPharm’), a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.
HiFiBiO Therapeutics announced a partnership with Russian pharmaceutical company, Pharmsynthez PJSC and Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS (IBCh).
Merck, through a subsidiary, has agreed to acquire clinical-stage biopharmaceutical company OncoImmune for an upfront cash payment of $425m.
Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.
The US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the potential to be the first BTK inhibitor for the treatment of immune thrombocytopenia (ITP).
Bristol Myers Squibb (BMS) has completed the acquisition of clinical-stage biopharmaceutical company MyoKardia for $13.1bn.
Lead Pharma has signed a collaboration and license agreement with Roche for the development of oral small molecules to treat a range of immune-mediated diseases.
Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of Lupin Limited (Lupin), announced today that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.